Stopping GLP-1s: What the Withdrawal Trials Show, and What Maintenance Really Means

The least marketed fact in this market is also the best measured one: stop the drug, and most of the weight comes back. In SURMOUNT-4, participants who lost 20.9% on tirzepatide and then switched to placebo regained about 14% of body weight within a year while continuers kept losing. In the STEP 1 extension, patients regained roughly two-thirds of semaglutide-driven loss in the year after stopping. This is not a flaw in the drugs; it is a fact about obesity.

Why regain is physiology, not weakness

Incretin therapy suppresses a hormonal appetite signal; it does not delete the system that generates it. Remove the drug and the biology of energy defense — elevated hunger signaling, reduced satiety response, the metabolic adaptation that accompanies any major loss — resumes exactly where it left off, now aimed at a body storing less energy. The clinical framing that fits the evidence is chronic-disease management, like hypertension: the medication treats while taken. Framing it as a "course" of treatment sets up the most predictable disappointment in the field.

What tapering can and cannot do

No trial shows a taper schedule that preserves full results after discontinuation — the regain curves in SURMOUNT-4 belong to abrupt switch-to-placebo, and gradual tapers are being studied, but "wean off and keep it all" currently has anecdote, not evidence. What does have evidence: lower-dose maintenance (holding a reduced dose after goal weight, which many clinicians use and flat-rate pricing makes cost-neutral), continued full-dose maintenance (STEP 5's flat two-year curve is what maintenance success looks like), and the muscle-and-protein work during the loss phase that determines the body composition you defend — the case made in the lean-mass guide. Behavioral infrastructure — training habit, protein floor, sleep, self-monitoring — is what partially "stays" when a drug stops; it moderated but did not prevent regain in the extensions.

The budget version of the truth

Because maintenance is plausibly indefinite, the honest cost of this therapy is an annual number, not a monthly teaser — which is why our database computes first-year totals and why maintenance-dose pricing, not starter pricing, anchors every ranking on this site. At 2026 rates, indefinite therapy runs roughly $2,580 a year at the cheapest verified compounded tirzepatide, $4,188 at the flat Wegovy rate, and $5,388 at Zepbound's maintenance tier — with Medicare's new ~$600/year Zepbound copay reality for eligible patients rewriting that math entirely. If a budget cannot sustain the maintenance number, that is a conversation to have before starting, with a prescriber who can discuss lower-dose strategies, coverage doors, and what an intentional off-ramp would realistically involve.